Cas:1239602-38-0 [8-(Glycidyloxy)-n-octyl]trimethoxysilane manufacturer & supplier

Chemical Name:[8-(Glycidyloxy)-n-octyl]trimethoxysilane

CAS.NO:1239602-38-0

Synonyms:Silane, trimethoxy[8-(oxiranylmethoxy)octyl]-;Trimethoxy[8-(2-oxiranylmethoxy)octyl]silane;MFCD29472534

Molecular Formula:C₁₄H₃₀O₅Si

Molecular Weight:306.470

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:335.5±22.0 °C at 760 mmHg

Density:1.0±0.1 g/cm3

Index of Refraction:1.446

PSA:

Exact Mass:306.186249

LogP:2.40

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Silane, trimethoxy[8-(oxiranylmethoxy)octyl]- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD29472534 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Trimethoxy[8-(2-oxiranylmethoxy)octyl]silane Use and application,Trimethoxy[8-(2-oxiranylmethoxy)octyl]silane technical grade,usp/ep/jp grade.

Related News: In taking control of Vanamali, Wavelength will double the firm’s production capacity and add more than 10 key regulatory starting materials and drug intermediates for Wavelength’s own strategic APIs and API CDMO customers, a Wavelength spokeswoman said by email. 7-Bromo-3-[2-[(2R)-2-methyl-1-pyrrolidinyl]ethyl]isoquinoline manufacturers In taking control of Vanamali, Wavelength will double the firm’s production capacity and add more than 10 key regulatory starting materials and drug intermediates for Wavelength’s own strategic APIs and API CDMO customers, a Wavelength spokeswoman said by email. Peptide,(Ser-Cys-Cys-Arg-Asp-Cys-Gly-Xaa-Asp-Cys-Val-Gly-Cys-Cys-Arg) suppliers It is always advisable for companies to start the clinical study responsibilities early on to combat unforeseen challenges that require more time. 3,5-diiodobenzonitrile vendor & factory During an investor event last month, Walmsley laid out her blueprint for the new GSK. It features a 5% average sales growth rate in the next five years, leading to total sales of £33 billion ($46 billion) by 2031.,During an investor event last month, Walmsley laid out her blueprint for the new GSK. It features a 5% average sales growth rate in the next five years, leading to total sales of £33 billion ($46 billion) by 2031.